Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment-Reference-Cited by-同舟云学术

Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment

Published:2023-06-28 Issue:9 Volume:98 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Naka Ryosuke¹,Kondo Tadakazu¹²^ORCID,Nishikubo Masashi¹,Muranushi Hiroyuki³,Ueda Yasunori³,Oka Tomomi²,Wada Fumiya²^ORCID,Kanda Junya²^ORCID,Yamamoto Shohei¹⁴,Watanabe Mitsumasa⁴,Okada Shinri⁵,Imada Kazunori⁵,Nakabo Yukiharu⁶,Mizutani Yu⁷,Nannya Yasuhito⁸⁹,Ogawa Seishi⁸,Ishikawa Takayuki¹

Affiliation:

1. Department of Hematology Kobe City Medical Center General Hospital Kobe Hyogo Japan

2. Department of Hematology and Oncology, Graduate School of Medicine Kyoto University Kyoto Kyoto Japan

3. Department of Hematology/Oncology and Transfusion and Hemapheresis Center Kurashiki Central Hospital Kurashiki Okayama Japan

4. Department of Hematology Hyogo Prefectural Amagasaki General Medical Center Amagasaki Hyogo Japan

5. Department of Hematology Japanese Red Cross Osaka Hospital Osaka Osaka Japan

6. The Center for Hematological Diseases Takeda General Hospital Kyoto Kyoto Japan

7. Department of Hematology Hyogo Prefectural Tamba Medical Center Tamba Hyogo Japan

8. Department of Pathology and Tumor Biology, Graduate School of Medicine Kyoto University Kyoto Kyoto Japan

9. Division of Hematopoietic Disease Control Institute of Medical Science, The University of Tokyo Tokyo Japan

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27012

Reference6 articles.

1. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

2. Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy

3. Next‐generation sequencing in two cases of de novo acute basophilic leukaemia

4. Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

5. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome